Vistide (cidofovir)
- Region
- 🇪🇺 EU
- Active substance
- cidofovir
- Company
- Gilead Sciences International Limited
- Status
- Withdrawn
- Therapeutic area
- Cytomegalovirus Retinitis
- EU approval
- Wed 23 Apr 1997
- Application
- EMEA/H/C/000121
- ATC
- J05AB12
- Official record
- www.ema.europa.eu
Indication
Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable.
Regulatory milestones
No milestones recorded in the last year.
Follow Vistide
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.